Regulatory News:
Cellectis (Paris: ALCLS), the French specialist in genome engineering has announced the appointment of Dr Mathieu Simon to the position of Senior vice-president.
Within the Cellectis group Mathieu Simon is in charge of developing therapeutic activities. In this capacity he will shortly be nominated president of each of the dedicated subsidiaries: Cellectis Therapeutics, Ectycell and Cellartis. Mathieu Simon will be responsible for the "Cellectis stem cell" business unit, created in 2011, which regroups the Cellartis and Ectycell subsidiaries, dedicated to "stem cell" activity.
Mathieu Simon is a member of Cellectis's executive committee.
André Choulika, chairman and chief executive officer of Group Cellectis, has expressed satisfaction at the arrival of Mathieu Simon, an internationally known expert in the pharmaceutical industry. "The arrival of Mathieu Simon will significantly enhance the capacity of Cellectis to become, in the near future, an essential economic actor. We expect him to play an active role in the generation of new commercial actions, to help launch innovative and efficient products on the market, and to fully participate in the growth of the Group's turnover". As for him, Dr Mathieu Simon has declared that "I take up this new challenge with enthusiasm. Cellectis is one of the most emblematic companies in the biotech sector and I happily join its ranks whose teams have built themselves a good reputation for scientific skill and innovative dynamism".
A 1982 graduate of the Paris Faculté de médecine, Dr Mathieu Simon has been active in the pharmaceutical field where, in an international career, he excelled at the highest level.
After having been Marketing & Sales Director at Wyeth France, Mathieu Simon became Group VP Marketing / Clinical Affairs for Wyeth Pharmaceuticals in the United States, where he was responsible for the marketing strategy of 5 business units. Mathieu Simon was then tasked with heading several of the most important regional subsidiaries of Group Wyeth (Benelux, Italy, Greece, The Balkans), with responsibility over several hundred million euros in turnover, as well as supervising 2 000 employees.
In 2010, Mathieu Simon was appointed Pharma Global Operations Senior vice president for Groupe Pierre Fabre Médicament.
Since 2011, he had been acting as advisor to financial institutions as well as to other companies of the sector.
About Cellectis
Cellectis improves the quality of life by applying its know-how in genome engineering to a broad range of applications, including human therapeutics, biological and agricultural research. Cellectis is listed on the Paris NYSE-Euronext Alternext market (code: ALCLS).
For more information, visit www.cellectis.com.
Disclaimer
This message, and the information it contains, is neither an offer to the public, nor a sales or subscription proposal for Cellectis shares in any country whatsoever.
Contacts:
Cellectis
Philippe Valachs, +33 (0)1-8169-1600
Secretary
General
media@cellectis.com
or
Profile
PR
Press relations
Leslie Boutin, +33 (0)1-5626-7233
lboutin@profilepr.fr
